Recruiting

OCS Solution & OFE

Sponsor:

TransMedics

Code:

NCT07145515

Conditions

Heart Transplant

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

OCS Heart

Static Cold Storage (SCS)

Study Details

Brief summary:

This trial is designed to evaluate the safety and effectiveness of the novel OCS Solution and OCS Functional Enhancer (OFE) to support FDA approval in both DBD and DCD heart transplantation. In addition, this trial will evaluate the performance of the novel OCS Solution and OFE compared to Static Cold Storage (SCS) in DBD heart transplantation to potentially demonstrate superiority.

Conditions

Heart Transplant

Study ID

NCT07145515

Start date

Jan, 2026

Status verified date

Jan, 2026

Completion date

Jul 30, 2027

Anticipated

Primary completion date

Jan 30, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Part A - DCD Donor Hearts \& DBD Donor Hearts Initially Deemed Unsuitable for Cold Storage (Current Approved Indications):

Donor Inclusion Criteria

  • Donor hearts are deemed clinically acceptable for transplantation after physical examination of the donor hearts in the donor chest and/or on the back table in the donor operating room.
  • All DCD donors eligible for functional warm ischemic time criteria ≤ 30 minutes. WIT defined as time from when mean systolic blood pressure (SBP) is <50mmHg (sustained for at least 5 minutes) to aortic cross clamp and administration of old cardioplegia in the donor.
  • DBD donor hearts with an expected cross clamp of ≥ 4 hours
  • DBD donor hearts with any of the following organ quality concerns, regardless of cross clamp time:

  • Donor age ≥ 40 years old
  • Unknown downtime
  • Insignificant CAD
  • LVEF ≤ 50%

Donor Exclusion • Moderate to severe aortic incompetence

Part B - DBD Donor Hearts Currently Used with Cold Storage (New Indication):

Donor Inclusion Criteria

  • Donor hearts are deemed clinically acceptable for transplantation after physical examination of the donor hearts in the donor chest and/or on the back table in the donor operating room.
  • Eligible for randomization to OCS or SCS treatment arms.
  • DBD donor hearts with an expected cross clamp time of < 4 hours.

Donor Exclusion

  • Moderate to severe aortic incompetence
  • DBD donor with any of the following organ quality concerns:

  • Donor age ≥ 40 years old
  • Unknown downtime
  • Insignificant CAD
  • LVEF ≤ 50%

Recipient Eligibility Criteria (for Part A and B Cohorts)

Inclusion

  • Signed informed consent document and authorization to use and disclose protected health information
  • Heart transplant candidate
  • Age ≥ 18 years old

Exclusion

• Participant in any other interventional clinical or investigational trials/programs that may confound the outcomes of this trial

Study Design

Enrollment

655 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Part A (OCS Heart)

DCD Donor Hearts \& DBD Donor Hearts Initially Deemed Unsuitable for Cold Storage (Current Approved Indications)

experimental: Part B (OCS Heart)

DBD Donor Hearts Currently Used with Cold Storage

active comparator: Part B (SCS)

DBD Donor Hearts Currently Used with Cold Storage

Interventions

OCS Heart

Preservation of donor hearts with OCS Heart System and novel OCS Solution and OCS Functional Enhancer.

Static Cold Storage (SCS)

Preservation of donor hearts with static cold storage.

Primary outcome measure

  • Patient and graft survival [ Time Frame: 30-day post transplant ]

Central Contacts and Locations

Locations

University of California San Francisco

Recruiting

San Francisco, California, United States, 94143

Contacts

Principal Investigator:

Liviu Klein, MD

Tampa General Hospital

Recruiting

Tampa, Florida, United States, 33606

Contacts

Principal Investigator:

Lucian Lozonschi, MD

Massachusetts General Hospital

Recruiting

Boston, Massachusetts, United States, 02114

Contacts

Principal Investigator:

David D'Alessandro, MD

Mount Sinai

Recruiting

New York, New York, United States, 10029

Contacts

Principal Investigator:

Anelechi Anyanwu, MD

Westchester Medical Center

Recruiting

Valhalla, New York, United States, 10595

Contacts

Principal Investigator:

David Spielvogel, MD

Duke University

Recruiting

Durham, North Carolina, United States, 27710

Contacts

Principal Investigator:

Jacob Schroder, MD

Baylor Scott and White

Recruiting

Dallas, Texas, United States, 75226

Principal Investigator:

Dan Meyer, MD

More Information

Sponsor

TransMedics

Last update posted

Jan 12, 2026

Last verified

Jan, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by TransMedics on 2026-01-12.